S. Wayne Kay, CEO of the Vancouver, B.C.-based Response Biomedical, a publicly traded manufacturer of equipment for clinical and environmental testing, has stepped down. Peter Thompson will serve as interim CEO while Responses board of directors oversees a search firm brought in to recruit a new CEO as quickly as possible, according to a press release announcing the transition.

The Plymouth Meeting, Pa.-based Healthcare Technology Foundation (HTF) is surveying healthcare workers who have knowledge of clinical alarm problems.

Members of the Institute of Medicine (IOM) Committee on the Public Health Effectiveness of the FDA 510(k) Clearance Process defend the findings of its recently released reportwhich recommended the FDA scrap its 510(k) process and start afreshin a perspective published Aug. 10 in the New England Journal of Medicine.

Telemedicine to a moving ambulance can improve the care of trauma patients, according to research published in the July issue of the Journal of Trauma.

AFC Industries has launched Hot Swappable Power Supply for its point of care, laptop and tablet carts.

Medtronic has issued a $2.5 million grant to Yale University, in New Haven, Conn., to independently review the safety and effectiveness of Infuse, the companys recombinant bone morphogenic protein-2 (rhBMP-2) product, which is used to stimulate bone formation, but has been linked to several side effects including male sterility.

Caliper Life Sciences of Hopkinton, Mass., and Carestream Health of Rochester, N.Y., have settled two lawsuits.

Bivalirudin (Angiomax, The Medicines Company) may be a viable alternative to heparin plus glycoprotein IIb/IIIa inhibitors (GPIs) in diabetic STEMI patients undergoing primary PCI, according to a substudy of HORIZONS-AMI trial results published in the July issue of JACC: Cardiovascular Interventions. In fact, patients who were administered bivalirudin saw reduced cardiac mortality at both 30 days and one year.